Indian pharmaceutical company
Natco Pharma |
| Company type | Public |
|---|
| NSE: NATCOPHARM
BSE: 524816 |
|---|
| Industry | Pharmaceuticals |
|---|
| Founded | 1981 |
|---|
| Founder | VC Nannapaneni |
|---|
| Headquarters | , India |
|---|
Area served | Global |
|---|
Key people | VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
|---|
| Revenue |  ₹4,784 crore (US$570 million) (2025) |
|---|
| ₹2,550 crore (US$300 million) (2025) |
|---|
| ₹1,883 crore (US$220 million) (2025) |
|---|
| Website | natcopharma.co.in |
|---|
Footnotes / references
Financials as of 31 March 2025[update].[3] |
Natco Pharma is an Indian multinationalpharmaceutical company based inHyderabad. The company manufactures finished dosage formulations,active pharmaceutical ingredients and agrochemical products.[4] It is a major producer of brandedoncology medicines[5] cardiology, diabetology and other pharma specialty drugs[6] at affordable prices.[7][8][9][10]
- Natco Pharma was founded in 1981 by V C Nannapaneni
- In 1983, operations commenced at manufacturing facility at Nagarjunasagar, Telangana
- In 1986, the company's chemical division started at Mekaguda, Telangana
- In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA,[11]
- In 2012, Natco Pharma obtainedcompulsory license to produce a cheaper and generic version ofBayer's anti-cancer medicationNexavar.[6]
- In the United States, it launchedinfluenza medicationTamiflu with marketing partnerAlvogen,multiple sclerosis treatment drugglatiramer acetate in partnership withMylan, andhepatitis C drugs under a licensing agreement withGilead Sciences.[11]
- In 2016, Natco Pharma launched the firstTamiflu capsule in the US market.[12]
- In 2017, Natco Pharma launched a generic version ofblood cancer drugPomalidomide in the United States.[13]
- In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products inNellore district,Andhra Pradesh.[14]
- In 2022, its Crop Health Sciences division launchedchlorantraniliprole (CTPR) based products.
- Natco launched the first generic version ofMultiple myeloma drugRevlimid in the US market
